MedTrace Logo

Supramaximal Walkouts and Back Squat Performance

NCT05988762 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-04-04

No results posted yet for this study

Summary

The goal of this randomized, counterbalanced, crossover study is to determine the effectiveness of performing a supramaximal walkout on enhancing subsequent back squat performance in trained lifters. The main question we aim to answer is whether bar velocity, power output, perceived exertion, and muscle activation are altered when performing the back squat exercise after a supramaximal walkout. On the first visit, participants will be informed of the study protocols before providing oral and written informed consent. Afterwards, participants will complete maximum voluntary isometric contraction (MVIC) testing for the quadriceps and gluteus maximus muscle groups to generate a normalization for the electromyography (EMG) measurements. During the second visit, participants will perform a 1RM back squat. The third and fourth visits will be the experimental visits, where they will perform either a supramaximal (110% 1RM) or submaximal (control; 30% 1RM) walkout. A set of 1 back squat at 92.5% 1RM will be performed prior to the walkout to serve as a baseline, then 3 sets of 1 at 92.5% 1RM will be performed afterwards.

Conditions

  • Healthy

Interventions

OTHER

Supramaximal Walkout

Walkout set performed at 110% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.

OTHER

Submaximal Walkout

Walkout set performed at 30% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.

Sponsors & Collaborators

  • Florida State University

    lead OTHER

Principal Investigators

  • Michael Ormsbee, PhD · Florida State University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-03-01
Completion
2024-03-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05988762 on ClinicalTrials.gov